Fundação Hospitalar do Distrito Federal.
UnB, Faculdade de Ciências da Saúde.
Braz J Otorhinolaryngol. 2013 Nov-Dec;79(6):727-33. doi: 10.5935/1808-8694.20130133.
Phosphodiesterase type 5 Inhibitors, such as sildenafil, vardenafil and tadalafil have been increasingly used today and some of the users have developed sudden sensorineural hearing loss.
To present two patients with sudden deafness developed after an occasional use of the drug and review studies on the use of phosphodiesterase type 5 inhibitors and sudden hearing loss.
Analytical study of two cases and review of the subject matter in the Pubmed/Medline and Bireme databases using the keywords: phosphodiesterase type 5 inhibitors and sudden deafness and its correlates in the English language.
The patients analyzed are young without additional disorders, using phosphodiesterase type 5 inhibitors, and after combination treatment for sudden hearing loss only one had hearing improvement. We found nine scientific studies and reviewed preclinical studies, clinical trials, prospective and cross-sectional investigations.
Increased occurrence in clinical practice and scientific reports in the literature suggest that the phosphodiesterase type 5 inhibitors are considered a risk factor for sudden deafness. Further studies with larger samples and control groups are needed for better assessing this association.
如今，磷酸二酯酶 5 型抑制剂（如西地那非、伐地那非和他达拉非）的使用越来越多，一些使用者出现了突发性感觉神经性听力损失。
报告两例偶尔使用该药物后发生突发性耳聋的患者，并复习磷酸二酯酶 5 型抑制剂与突发性听力损失相关的研究。
对两例病例进行分析，并在 Pubmed/Medline 和 Bireme 数据库中使用关键词：磷酸二酯酶 5 型抑制剂、突发性耳聋及其在英语中的相关性进行主题回顾。
分析的患者均为年轻、无其他疾病，使用磷酸二酯酶 5 型抑制剂，联合治疗突发性听力损失后仅 1 例听力有所改善。我们发现了 9 项科学研究，并回顾了临床前研究、临床试验、前瞻性和横断面研究。
临床实践和文献中的科学报告中发病率的增加表明，磷酸二酯酶 5 型抑制剂被认为是突发性耳聋的一个危险因素。需要进一步进行更大样本量和对照组的研究，以更好地评估这种相关性。
